Aphase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®) alone when initiated within three hours of acute ischemic stroke onset.
IMPORTANT STUDY ANNOUNCEMENT:
The DSMB recommends that enrollment into the IMS-III study be put on hold, effective immediately. Subject follow-up should continue. The DSMB noted that there are no serious safety concerns. The study investigative team should remain blinded at this time. NINDS concurs with the IMS-III DSMB recommendations.
View the NINDS staement here: http://www.ninds.nih.gov/disorders/clinical_trials/IMS-III.htm